1098 Anti-inflammatory and antibacterial drug delivery nanocarriers for the topical treatment of MRSA-induced systemic and localized infections

S. aureus infection causes several skin diseases, such as impetigo, carbuncles, folliculitis, etc. Irritation and some discomforts are also frequently reported. What’s worse, the sometimes penetrates through epidermis, causing a necrotic ulcer—ecthyma. These infections characterized clinically by abrupt tissue destruction, systemic signs of toxicity, high mortality [Dennis L. Stevens, 2022]. Bacterial common in most developing countries [Roderick Hay, 2006]. Our immune system is required to control bacterial infection, but it may lead severe inflammation when overreacting. As abundant white blood cells our blood, neutrophils play an essential role early pathogen invasion their first recruitment inflamed lesions burst release cytokines. However, cytokine storm damage occur uncontrollably. Therefore, study aims simultaneously inhibit overactive responses invading antibiotic-resistant bacteria—MRSA. We developed kind polymeric nanoparticles enclosing roflumilast fusidic acid sodium reduce side effects increase drug concentration accumulated at sites. Moreover, we conjugated antibodies modify encapsulating (RFL-PNPs) specifically target neutrophils, main character innate immunity, disrupt activation. Among all formulations, group combination NPs-RFL-Ab NPs-FAS showed significant inhibition killing MRSA inhibiting cytokines IL-6, TNF-α, CXCL2. By designing decorated with NIMP-R14, hope improve strategy for treating MRSA-related disease cell animal experiments.